No Data
No Data
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $Sagimet Biosciences(SGMT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.5% and a total average return of 7.4% over the p
Express News | Sagimet Biosciences To Host Conference Call And Webcast On June 13, 2024, To Discuss Positive Data From FASCINATE-2 Phase 2b Trial Of Denifanstat In MASH Patients Presented At EASL Congress
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data From ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to
Sagimet Biosciences Price Target Maintained With a $48.00/Share by JMP Securities
Sagimet Biosciences Price Target Maintained With a $48.00/Share by JMP Securities
Express News | HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
What's Going On With Sagimet Biosciences Stock On Thursday?
Sagimet Biosciences Inc (NASDAQ:SGMT) presented data from its FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MA
No Data